Amplifying Immune Responses: Microparticulate Vaccine Approach Against Breast Cancer

Michelle Marie Ubowski,1 Ryan VanSice,1 Morgan Marriott,1 Matthew J Yacobucci,2 Lipika Chablani1 1Wegmans School of Pharmacy, St. John Fisher University, Rochester, NY, 14618, USA; 2Albany College of Pharmacy and Health Sciences, Albany, NY, 12208, USACorrespondence: Lipika Chablani, Department of Pharmaceutical Sciences, Wegmans School of Pharmacy, St. John Fisher University, 3690 East Ave, Rochester, NY, 14618, USA, Tel +1-585-899-3714, Fax +1-585-899-8453, Email [email protected]: The study focuses on evaluating the immune responses generated by a novel microparticulate murine breast cancer vaccine.Methods: The methodology included the use of a co-culture model of dendritic cells (DCs), and T-cells to evaluate the immunotherapeutic responses generated by the vaccine.Results: The study observed that the dendritic cells expressed significantly higher levels of MHC I, MHC II, CD 40, and CD 80 cell surface markers in the presence of the vaccine microparticles than the controls (p< 0.05). This response was potentiated in the presence of an adjuvant, Poly (I:C). The study also demonstrated that the vaccine microparticles do not elicit inflammatory (TNF-alpha, IFN-gamma, IL-2, and IL-12) or immunosuppressive (IL-10) cytokine production when compared to the control.Discussion: In conclusion, the study established the role of DCs in stimulating the cancer vaccine’s adaptive immune responses.Keywords: dendritic cells, adjuvants, poly I:C, adaptive immune response, vaccine formulatio